Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

NCT00088595 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoid Tumors

Interventions

DRUG: Pasireotide (SOM230)

Sponsor

Novartis Pharmaceuticals